Looks as if MPS Medical website updated to reflect on Innova Medical Group's previous acquisition:
Innova Medical Group's PR concerning the acquisition of MPS as of January 4th, 2021:
Innova Medical Group expands U.S. production of COVID-19 Rapid Antigen Tests with acquisition of California-based MPS Medical, Inc.
MPS Medical, Inc. develops and manufactures medical devices to advance healthcare across multiple areas of care. Its 30-year company history began in 1990 as MPS Acacia. In 2014, MPS Medical began manufacture of MPS Acacia’s market leading neonatal intensive care products and has since expanded into multiple successful divisions. These include infusion therapy, cell therapy manufacturing, sterile compounding, and in-home pharmacy, as well as OEM services. Its custom manufacturing capabilities enable clinical professionals to create new products to meet the specific needs of their patients. MPS Medical, Inc. maintains Class 7 cleanrooms for production in its Brea, California facilities.
MPS also mentions QMC Health ID on it's front page:
INNOVA leads in the manufacture and distribution of rapid antigen and antibody test kits for COVID-19 disease detection.?
INNOVA’s integrated solution provides a best-in-class portfolio of diagnostic and screening tests. QMC HealthID™ secure app captures test results and creates a “health passport” for the user. Analytics, powered by real-time data, assist in tailoring protocols to individual use cases: entertainment, government, manufacturing, nursing and care homes, schools and universities and transportation.
With the advent of Pasaca Capital entering into a distribution agreement with Quantum Materials Corp, we can easily speculate
that QMC's Quantum Dots can/will be used for Innova/MPS's medical devices (other than the lateral flow tests), either through anti-counterfeiting or other means:
Distribution Agreement. On January 26, 2021, the Company and Pasaca entered into a Distribution Agreement (the “Distribution Agreement”). P ursuant to the terms of the Distribution Agreement, the Company appointed Pasaca to act as an independent distributor to resell and distribute the Company’s Quantum Dots and QMC HealthID products. Under the Distribution Agreement, Pasaca guaranteed that the Company would receive cumulative gross royalties and/or gross sales, licensing or other revenues under the Distribution Agreement of no less than $15,000,000, over the period including 2020 and continuing until twelve months after the Company has completed development of a functioning product integrating the QMC HealthID IP and Innova Medical Group’s products. Pasaca has the right to extend the revenue period by up to twenty-four months upon payment of advance royalties.
This is well within the "Life Science" sector QMC spoke about within it's 10K underneath it's "Sales and Marketing Overview" section:
Our discussions with Life Science companies provide strong evidence that the market opportunity is substantial and that our business plan is aligned with the customers’ product specification needs. While we are pursuing applications in several other markets as well, we believe that the Life Sciences and anti-counterfeiting represents the most substantial and most immediate opportunities. We further believe that our advantages in delivery of large volumes of high quality, narrow spectra, high performance QDs and other nanomaterials via our patented continuous production process makes us an attractive supplier. While we continue to pursue direct sales opportunities, we are also pursuing license agreements with strategic partners that can accelerate adoption in key verticals.